Artivion, Inc. 2026 Q3 - Results - Earnings Call Presentation
AORT Q3 2026 deep dive: stent graft growth and NEXUS launch preparations shape outlook
Artivion (AORT) Stock Looks About Right Following Nexus Launch Preparations
Is Artivion (AORT) Undervalued Following Mixed Earnings And A Return To Losses?
Artivion Q3 Earnings Call Highlights
Canaccord Genuity Maintains Buy on Artivion, Lowers Price Target to $30
Citizens Maintains Market Outperform on Artivion, Lowers Price Target to $42
Artivion Inc (AORT) (Q3 2026) Earnings Call Highlights: Stent Graft Momentum and Nexus Launch ...
What Artivion (AORT)'s Revenue Growth And Loss Mean For Shareholders
Artivion (AORT) Q3 2026 Earnings Call Transcript
ARTIVION INC (NYSE:AORT) Q3 EPS Beat Meets Inline Revenue
Artivion’s (NYSE:AORT) Q3 2026 sales beat estimates
Artivion: Q3 Earnings Snapshot
Artivion Reports Third Quarter 2026 Financial Results
Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
Artivion Q3 2026 Earnings Call Transcript
Artivion Narrows FY2026 Sales Guidance from $480.000M-$496.000M to $484.000M-$492.000M vs $490.600M Est
Artivion Q3 Adj. EPS $0.08 Beats $(0.06) Estimate, Sales $123.800M Beat $120.738M Estimate
Artivion to Participate in Upcoming Investor Conferences
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.